TRCT
CORV

Tower Research Capital (TRC)’s Correvio Pharma Corp. Ordinary Shares (Canada) CORV Stock Holding History

Tower Research Capital (TRC)’s Portfolio CORV Stock Details CORV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,171
Closed -$3K – 4817
2019
Q3 		$3K Buy
+1,171
New +$2.37K ﹤0.01% 3634
2019
Q2 		– Sell
-1,652
Closed -$5K – 4653
2019
Q1 		$5K Sell
1,652
-661
-29% -$2.14K ﹤0.01% 3125
2018
Q4 		$6K Buy
2,313
+930
+67% +$3.1K ﹤0.01% 2856
2018
Q3 		$6K Buy
+1,383
New +$6.1K ﹤0.01% 3079
2017
Q2 		– Sell
-2,593
Closed -$10K – 3780
2017
Q1 		$10K Buy
2,593
+1,562
+152% +$4.61K ﹤0.01% 1805
2016
Q4 		$4K Sell
1,031
-226
-18% -$646 ﹤0.01% 3194
2016
Q3 		$4K Buy
1,257
+757
+151% +$2.76K ﹤0.01% 2761
2016
Q2 		$3K Sell
500
-1,342
-73% -$6.45K ﹤0.01% 3787
2016
Q1 		$7K Buy
1,842
+1,301
+240% +$6.96K ﹤0.01% 2446
2015
Q4 		$4K Sell
541
-876
-62% -$7.3K ﹤0.01% 3310
2015
Q3 		$11K Sell
1,417
-3,679
-72% -$33.9K ﹤0.01% 2269
2015
Q2 		$48K Buy
5,096
+996
+24% +$9.28K ﹤0.01% 1403
2015
Q1 		$38K Sell
4,100
-1,333
-25% -$12.8K ﹤0.01% 1711
2014
Q4 		$51K Buy
5,433
+2,065
+61% +$17.4K ﹤0.01% 1026
2014
Q3 		$34K Buy
3,368
+34
+1% +$247 ﹤0.01% 1872
2014
Q2 		$28K Buy
3,334
+2,034
+156% +$15.4K ﹤0.01% 1648
2014
Q1 		$12K Buy
1,300
+800
+160% +$6.44K ﹤0.01% 2460
2013
Q4 		$3K Sell
500
-1,558
-76% -$8.17K ﹤0.01% 3903
2013
Q3 		$7K Buy
+2,058
New +$4.68K ﹤0.01% 3484

Other funds holding CORV

TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tower Research Capital (TRC)'s CORV Position: Q4 2019 in Review

Tower Research Capital (TRC) sold out of Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) in Q4 2019, closing a stake of 1,171 shares — an estimated $3K sold.

Tower Research Capital (TRC) first reported a position in CORV in Q3 2013 and held it in 19 quarters. The position peaked at $51K in Q4 2014. 31 funds tracked by Wall St. Rank hold CORV as of Q4 2019.

  • Tower Research Capital (TRC) reported no remaining Correvio Pharma Corp. Ordinary Shares (Canada) position as of Q4 2019 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,171 Correvio Pharma Corp. Ordinary Shares (Canada) shares in Q4 2019, an estimated $3K.
  • Tower Research Capital (TRC) first reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) in Q3 2013 and held it in 19 quarters.
  • Tower Research Capital (TRC)'s Correvio Pharma Corp. Ordinary Shares (Canada) position peaked at $51K in Q4 2014.
  • 31 funds tracked by Wall St. Rank held Correvio Pharma Corp. Ordinary Shares (Canada) as of Q4 2019.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2019, filed 7 Feb 2020.